Safety and tolerability of empagliflozin and linagliptin combination therapy in patients with type 2 diabetes mellitus: a pooled analysis of data from five randomized, controlled clinical trials

• Hirotaka WatadaJuntendo University
• Toshimasa YamauchiThe University of Tokyo
• Fumiko YamamotoBoehringer Ingelheim (Japan)
• Atsushi TaniguchiBoehringer Ingelheim (Japan)
• Larisa YarushBoehringer Ingelheim (United States)
• Clemens J. HeilmannBoehringer Ingelheim (Germany)
• Atsutaka YasuiBoehringer Ingelheim (Japan)